Cardinal Health Inc vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Cardinal Health Inc trades at $241.5 (market cap $55.55B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77. The key difference: Cardinal Health Inc pays a 0.86% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| CAH | FLRN | |
|---|---|---|
Market Cap | $55.55B | — |
Sector | Health | Sector/Thematic |
52-Week High | $240.26 | $30.86 |
52-Week Low | $146.04 | $30.65 |
Enterprise Value | $60.53B | — |
Dividend Yield | 0.86% | — |
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $236.4, down 0.53% on the day, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The company reported $222.58B in revenue for 2025, with net income rising to $1.56B, and recently announced two home-care acquisitions to expand its at-Home Solutions segment. Analyst sentiment is positive, with a consensus price target of $262.80 and no sell ratings among 33 analysts.
The stock presents a favorable risk-reward profile with upside to the consensus target, supported by earnings beats and strategic growth initiatives. Key risks include high leverage with a debt-to-asset ratio of 16.09 in 2025 and thin net margins of 0.62%, which could pressure profitability if revenue growth slows or interest costs rise.
FLRN trades at $30.76 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data. Recent dividend payments of $0.11 suggest stable income distribution, but fundamental analysis is limited without updated financial statements.
Outlook remains cautious due to bearish technical signals and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to assess profitability and growth. Primary risks include market volatility and reliance on future earnings reports for valuation clarity. Investors should await Q2 2026 results for deeper insight.
Trailing returns across standard periods
Latest headlines on both assets
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →